Subscribe
Lilly Resubmits Cymbalta® Supplemental New Drug Application For Chronic Pain To U.S. Food And Drug Administration 
PharmaceuticalOnline | Wed, Jun 3
As projected, Eli Lilly and Company (NYSE: LLY ) has resubmitted its supplemental New Drug Application (sNDA) for Cymbalta® (duloxetine HCl) for the management of chronic pain to the U.S. Food and Drug Administration (FDA). Lilly's resubmission is based on a recently completed study in c...
Try These Related Topics
Related News
Risks associated with opioid pain medications may outweigh surgery risks
Study Reveals Predictors Of Long-term Opioid Use For Back Pain
Widely used device not recommended for chronic low back pain
TENS therapy is not effective against chronic low-back pain
Widely used device for pain therapy not recommended for chronic low back pain
Guideline: Widely Used Device For Pain Therapy Not Recommended For Chronic Low Back Pain
Top Bloggers
| 1 | Breaking Health New... |
| 2 | volunteers in new y... |
| 3 | Reuters Health eLine |
| 4 | Dr Davis' Back & Wr... |
| 5 | Ortho SuperSite |
| 6 | pottsmerc.com |
| 7 | health.usnews.com |
Photo Gallery
Opinion: Therapy, Meds Best for Lumbar Low Back Pain
NY - The review authors found that in 90 percent of people with low back pain, symptoms disappear on their own within three months and that most of those ...
Wed, Feb 4 | from Health.com
